Inveready leads €600,000 round for Ojer Pharma

Inveready drew down capital from Inveready Innvierte Biotech II, which holds €15.5m. Several of the company's existing investors also participated in the funding round.

The company will use the fresh funding to bring its latest projects to market and boost the development of its portfolio of dermatological products.

Previous funding
In 2007, funds managed by Clave Mayor committed €475,000 to the business to support the development of specialist products. 

In 2011, Corporación Caja Navarra (CAN), the private equity arm of Caja Navarra, invested €500,000 in Ojer Pharma in return for a 11.22% in the business, according to unquote" data.

Sociedad de Desarrollo de Navarra, the investment arm of the government of Navarra, is also represented in the company's shareholding structure.

Company
Established in 2005 as a spinout of the University of Navarra, Ojer develops prescription medicines and pharmaceutical products for dermatological problems.

People
Sara Secall is investment director at Inveready.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Southern Europe
• Healthcare
• Expansion
• Spain
• Inveready First Capital